Teleflex AI Stock Analysis
Teleflex (TBH) AI Stock Analysis
Teleflex
(BX Swiss:TBH)
No summary available
Teleflex Business Overview & Revenue Model
Company Description
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within cri...
Teleflex Earnings Call Summary
The call was predominantly positive. Teleflex delivered better-than-expected third-quarter EPS, expanded margins, reduced leverage, completed significant share repurchases, maintained its revenue outlook, and raised full-year EPS guidance. The company also reported progress on the Interventional integration, organizational transformation, innovation programs, and planned cost savings. These positives were tempered by continued Interventional integration disruption, uncertainty around the timing of the Acute Care and Interventional Urology divestiture, ongoing tariff exposure, near-term R&D and investment-related margin pressure, and the gradual ramp expected for EZPLAZ.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Teleflex continues to expect 2026 pro forma adjusted constant currency revenue growth in the range of 3.5% to 4.5% and raised adjusted EPS guidance to $7.50 to $7.75 from $6.90 to $7.20, including a $0.31 benefit from IEEPA tariff refunds; foreign exchange is now expected to be approximately $9 million to $10 million benefit to reported revenue, adjusted operating margin approximately 20%, net interest expense approximately $85 million, adjusted tax rate approximately 11.5%, and shares outstanding approximately 42.5 million. Once the Acute Care and Interventional Urology divestiture closes, operating margin is expected to approximate 23% in year 1, while the divestiture is targeted to close by year-end but could extend into 2027; the multiyear restructuring plan is expected to achieve approximately $50 million in annual pretax cost savings upon completion in mid-2028. Interventional is targeting a modest sequential improvement quarter-over-quarter, with mid-single-digit end markets, and EZPLAZ revenue is expected to be immaterial in 2026, become a contributor in 2027, and have a modest revenue ramp over the first several years against a potential U.S. market opportunity of at least $200 million; tariffs are currently approximately a little over $30 million and expected to be similar for 2027.
Teleflex Risk Analysis
Teleflex disclosed 34 risk factors in its most recent earnings report. Teleflex reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksTeleflex Peers Comparison
Overall Rating
MMSI71Outperform
ICUI64Neutral
BDX63Neutral
BAX53Neutral
ANGO52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | $5.06B | 31.35 | 9.65% | ― | 9.34% | 33.77% | |
| 64Neutral | $4.40B | 71.58 | 2.81% | ― | -5.82% | ― | |
| 63Neutral | $57.93B | 51.27 | 4.64% | 1.87% | -7.40% | -28.89% | |
| 53Neutral | $13.14B | -18.40 | -11.62% | 0.16% | 5.33% | -164.67% | |
| 52Neutral | $452.51M | -13.68 | -19.25% | ― | 8.20% | -0.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ANGO | Angiodynamics, Inc. | 10.81 | -1.49 | -12.11% | |
| BAX | Baxter International Inc | 25.39 | 7.25 | 39.93% | |
| BDX | Becton, Dickinson and Co | 212.78 | 66.38 | 45.34% | |
| ICUI | ICU Medical | 172.52 | 23.98 | 16.14% | |
| MMSI | Merit Medical | 84.34 | -2.83 | -3.25% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
